Fragile X syndrome (FXS) is the most common inherited form of intellectual disability, typically due to CGG-repeat expansions in the FMR1 gene leading to lack of expression. We identified a rare FMR1 gene mutation (c.413G>A), previously reported in a single patient and reviewed the literature for other rare FMR1 mutations. Our patient at 10 years of age presented with the classical findings of FXS including intellectual disability, autism, craniofacial findings, hyperextensibility, fleshy hands, flat feet, unsteady gait, and seizures but without the typical CGG-repeat expansion. He had more features of FXS than the previously reported patient with the same mutation.
| INTRODUCTION
Fragile X syndrome (FXS) is the most commonly inherited cause of intellectual disability and as an X-linked genetic disorder occurs more frequently in males. Social impairment, autism spectrum disorder, speech and language delay, neurological dysfunction (seizures and abnormal sleep patterns) and a characteristic physical appearance are also observed. FXS occurs in 1 in 5,000 males (Coffee et al., 2009; Hagerman & Hagerman, 2002) caused by expansions of a CGG triplet repeat in the 5′ untranslated region of the familial mental retardation 1 (FMR1) gene located on the X chromosome. The expansion of trinucleotide CGG repeats leads to transcriptional silencing of FMR1 with consequent absence of the encoded fragile X mental retardation protein (FMRP), a synaptic RNA-binding protein that functions to modulate action potential duration and synaptic plasticity (Myrick, Hashimoto, Cheng, & Warren, 2015) . This repeat expansion is seen in greater than 99% of affected individuals. Rare mutations have been reported in the promoter or coding regions of the gene in individuals with features of FXS (Collins et al., 2010; De et al., 1993; Grozeva et al., FXS while unaffected individuals have 6-44 CGG repeats. Individuals with a premutation harbor an allele with 55-200 CGG trinucleotide repeats in FMR1, and are at risk for further expansion in subsequent generations, as well as for primary ovarian failure and tremor ataxia syndrome (Garber, Visootsak, & Warren, 2008; Hagerman & Hagerman, 2013; Myrick et al., 2014) .
Patients with FXS and the CGG expansion in FMR1 typically present with large, protruding ears, elongated face, highly arched palate, hyperextensible finger joints, flat feet, soft skin, postpubescent macroorchidism, and hypotonia (Regezi, Sciubba, & Jordan, 2008; Santoro, Bray, & Warren, 2012) . They also have an increased risk of developing seizures and mitral valve prolapse with features of a connective tissue disorder (Berry-Kravis et al., 2010; Hagerman et al., 2009; McLennan, Polussa, Tassone, & Hagerman, 2011) . The FMR1 gene is highly expressed in brain and testicular tissue consistent with abnormalities observed in FXS including intellectual disability, behavioral problems, seizures, characteristic facial features, autism spectrum disorder, and macroorchidism.
Although FXS is usually caused by an expansion of the CGG repeat of (Myrick et al., 2014) . This reported patient had intellectual disability and intractable seizures associated with FXS. Animal models demonstrated that this mutation preserves the translational regulation abilities of FMRP and also post-synaptic regulation of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor trafficking, polyribosome association, and mRNA binding (Myrick, Deng, et al., 2015) . However, pre-synaptic functions, such as rescuing synaptic overgrowth and action potential in the hippocampus and pyramidal neurons combined with regulation of the BK channels are disrupted by this missense mutation suggesting a differential and distinct functional FMRP role in pre-synaptic versus post-synaptic regions (Myrick, Deng, et al., 2015 . Additional information on FMRP function could be gained by reporting subjects with rare mutations of FMR1 other than the typical triplet CGG repeat expansion as the causation of FXS. In a literature review, 20 affected individuals were found with mutations of the coding sequence of FMR1 consisting of 17 exons spanning 38 kb (Collins et al., 2010; De et al., 1993; Grønskov, Hallberg, Brøndum-Nielsen, Dedic, & Hjalgrim, 2011; Grozeva et al., 2015; Handt et al., 2014; Hu et al., 2016; Lugenbeel et al., 1995; Myrick et al., 2014; Quartier et al., 2017; Suhl & Warren, 2015; Wang, Lin, Lin, Li, & Li, 1997; Wright et al., 2015) . 
| MATERIALS AND METHODS

| Clinical report
Our patient with an FMR1 allele in the normal size range, presented with FXS due to a missense mutation in exon 5 of FMR1. He was the product of a full-term uncomplicated pregnancy with the mother and father being first cousins of Portuguese decent. His birth weight was 7 lb, 7 oz (3.3 kg). No physical abnormalities were noted at birth following a full term vaginal delivery. There were no neonatal or feeding problems. He was unable to sit independently until 9 months of age and began walking at 16 months but did not develop recognizable speech and relied on six signs for communication. At 27 months of age due to developmental delays and behavioral concerns, cognitive, and behavioral tests were performed and an autism spectrum disorder (ASD) diagnosis made. At 3 years of age, corrective surgery was performed for strabismus and bilateral esotropia. His tonsils and adenoids were removed at age 4 years.
He had an abscess of a tooth which was surgically removed at 8 years of age followed by a second procedure to remove an abscess on his back at 9 years of age. An evaluation at 4 years 8 months of age revealed a nonverbal status and cognitive functioning at a 14-16 months level. His verbal cognitive score was determined to be less than 12 months of age.
The Autism Diagnostic Observation Schedule, Childhood Autism Rating Scale, and Social Responsiveness Scale were administered and all indicated a diagnosis of ASD.
He was also diagnosed with attention deficit hyperactivity disorder At 10 years of age he was slender with a height of 136 cm (35th centile), weight 25.7 kg (10th centile), head circumference 51.8 cm (25th centile), inner canthal distance 3 cm (50th centile), outer canthal distance 8.1 cm (30th centile), interpupillary distance 5.2 cm (30th centile), palpebral fissure length 2.6 cm (30th centile), ear length 6 cm (60th centile), and ear width 3.8 cm (20th centile). He was rated at a Tanner stage I level of pubertal development. He had multiple features associated with FXS including a large wide mouth with drooling, a large jaw, elongated face, broad ears, soft fleshy hands, hyperextensible digits (metacarpo-phalangeal extension greater than 90°for most digits with double jointed thumbs), and a single palmar crease. His genito-urinary examination showed a normal sized penis without hypospadias, normal testicular volume (3-4 ml), and a mild shawl scrotum. He exhibited hyperactivity and an unsteady gait with toe walking and was unable to tandem walk. His feet were flat with a mild degree of pronation. His resting motor tone was decreased except when excited and exhibited hand flapping. He did not show tremors. Additionally, his large ears showed unusual folding of the pinna bilaterally. He did not have epicanthal folds, ptosis, scoliosis, pectus excavatum, dental abnormalities, hernias, heart murmurs, plantar creases, or self-injury sites (see Figure 1) . He also exhibited the groaning or moaning characteristic of non-verbal children with FXS. However, overall he was more affected cognitively and behaviorally than the typical child with FXS as he was non-verbal with severe behavioral problems.
On examination at 10 years of age, he was assessed using the ADOS-2 module 1 social affect score was 18, repetitive and restrictive behavior was 6 and his total score was 24 in the severe ASD range. He was treated with risperidone, which can be helpful for those with both ASD and FXS and he responded well with a decrease in hyperactivity.
Guanfacine has also been helpful to calm his behavioral problems and he also continues to take Trileptal for seizures. This point mutation has been reported previously in one patient presenting with seizures and intellectual disability . Our patient also presented with intellectual disability and seizures consistent with the previously reported patient with the same missense mutation. Additionally, he had ASD, ADHD, and several typical features of FXS including characteristic facial features (large upper face, small lower face, and prominent broad ears), hyperextensible digits, soft fleshy hands, flat feet, unsteady gait, hypotonia, and strabismus.
FMRP transports mRNA from the neuronal nuclei to the synapses with selectivity specific for many pre-and post-synaptic targets.
Individuals with FXS have abnormal dendritic spines in the brain which are important for increasing the surface area of synaptic connections involved in neuroplasticity (Bassell & Warren, 2008; Bhakar, Dölen, & Bear, 2012; Garber et al., 2008) . FMRP is also involved in several postsynaptic signaling cascades including acetylcholine, dopamine, and glutamate receptor signaling (Osterweil, Krueger, Reinhold, & Bear, 2010; Volk, Pfeiffer, Gibson, & Huber, 2007; Wang et al., 2008) . In addition to facilitating mRNA transport and post-synaptic functions, FMRP is also found in structures in axons and pre-synaptic terminals called fragile-X granules expressed during periods of synaptic plasticity.
FMRP regulates expression of dendritic voltage-gated K+ channels in
brain circuits and affects the activity of several pre-synaptic voltagegated ion channels (Myrick et al., 2014) . It also regulates the expression of the sodium-activated potassium channel Slack, post-synaptic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) involved in synaptic plasticity and adaptation, and n-type voltage-gated calcium channels Cav2.2 (Ferron, Nieto-Rostro, Cassidy, & Dolphin, 2014) . Finally, FMRP modulates activity of largeconductance calcium-activated potassium (BK) channels found in the hippocampal and cortical excitatory neurons, critical for regulating action potential duration playing a role in seizure propagation (Bhakar et al., 2012; Brenner et al., 2005; Deng et al., 2013; Grønskov et al., 2011; Myrick et al., 2014; Shruti, Clem, & Barth, 2008) . In animal models, the mutation seen in our patient has been linked specifically to impairments of the pre-synaptic functions of FMRP such as regulation of BK channels and prevention of synaptic overgrowth (Brenner et al., 2005; Deng et al., 2013; Shruti et al., 2008) . The role of BK channels in seizures may partially explain why seizures were among the FXS symptoms reported in both of these patients. Interestingly, post-synaptic functions of FMRP such as translational regulation, mRNA binding, and AMPA receptor trafficking were all preserved in the animal models with this missense mutation.
Several mutations affecting FMR1 have been recorded in the literature including those in the promoter region in three males younger than 18 years of age with unexplained developmental delay not due to the typical CGG repeat expansion. The three promoter mutations, located at c.-332G>C, c.-293T>C, and c.-254A>G, showed reduced FMR1 promoter activity in luciferase studies at 5.9%, 29.2%, and 36.2%, respectively, of wild-type levels and were likely pathogenic (Collins et al., 2010) . In addition, both missense and nonsense mutations and deletions or disturbances of the coding sequence were reported in 20 patients and clinical information supporting FXS or FXS-like symptoms were described in 17. Five separate 15 causing a nonsense mutation 1457insG; three brothers with the same nonsense mutation in exon 17 causing a frameshift change r.1737_1738ins1737+1_?, p.Ile580fs*9; a frameshift causing skipping of exon 10 at c.990+1G>A, p.Lys295Asnfs*11; a nonsense mutation at c.80C>A in exon 2, p.Ser27X resulting in a frameshift and premature termination of the protein and a one base pair change at c.373delA in exon 5, p.Thr126Leu and a nonsense mutation in exon 6 at c.420-8A>G, p.Met140Ilefs*3. A single 3′UTR change of unknown significance at genomic location c.*746T>C has been reported (see Table 1 ).
All variants listed above are a mixture of pathogenic, likely pathogenic, and variants of uncertain significance (VUS) as defined by the American College of Medical Genetics and Genomics (ACMG) consensus criteria using standards with guidelines for the interpretation of sequence variants (Richards et al., 2015) . In general, rare structural variants, such as nonsense or frameshift, in a gene that has strong congruence with the clinical phenotype can be classified as likely | 15 pathogenic or pathogenic. Rare missense variants need more evidence to rise to the level of pathogenicity, such as functional data or presence in multiple patients. Based on this criteria, we have classified each of the 17 gene variants as pathogenic, likely pathogenic or VUS (see Table 1 ).
The FMR1 gene encodes FMRP which has an amino terminal domain consisting of structural modules, a tandem array of two Agenet/Tudor domains (Agenet 1 and 2) located at amino acid residues 4-50 and 63-115, respectively, with RNA binding activity (Lacoux et al., 2012) and NLS (nuclear localization signal) at amino acid residues 115-252 followed by K homology (KH) domains at KH0 (residues 63-113), KH1 (residues 221-266), and KH2 (residues 285-328). The NES (nuclear export signal) is located at residues 422-446 and followed by C-terminus arginine-glycineglycine (RGG) residues located at 527-552 which also binds RNA (Myrick, Deng, et al 2015; Quartier et al., 2017) .
The interface between Agenet and KH domains involve a large number of aromatic and hydrophobic forces and intra-molecule interactions that confer stability. The Agenet domain contains an aromatic cage with binding potential to methylated lysine and histones (Alpatov et al., 2014) .
All subjects reported were male when sex information was available and ranged in age from infancy to 50 years. Two of the males had height and weight at or above the 95th centile indicating a large size reported in some individuals with FXS. Dysmorphic features included craniofacial findings with an elongated face, high broad forehead, prominent ears and hypermobile joints in the majority of reported males consistent with FXS. Most subjects were verbal with limited speech and/or had autism and hyperactivity; all had developmental delays or intellectual disability.
Seizures, rapid cluttered speech and enlarged testicles were also seen as common features in FXS (see Table 1 ). One adult male had a testicular volume of greater than 100 ml. Our family had a history of consanguinuity (parents were first cousins) and thus at risk for rare genetic conditions involving an area of homozygosity. Homozygosity mapping followed by exome sequencing to identify homozygous variants in genes associated with autism or intellectueal disability was not undertaken. The gene panel utilized would not have covered all known associated genes nor any new genes. This is a potential limitation and a possible alternative cause of his condition that cannot be ruled out. Our study suggests that additional patients meeting the clinical criteria for FXS but with normal testing without the CGG repeat expansion may have other mutations of the gene. Next generation sequencing and further genetic testing beyond the triplet repeat mutation analysis should be performed as standard DNA test to rule out FXS in our patient when tested at 3 years of age did not identify the typical FMR1 triple repeat mutation. In addition, his mother and teenage sister were tested and found to carry the same rare FMR1 gene mutation with a profound impact on genetic and reproductive counseling and risk estimates.
Finally, the existence of other subsets of FXS patients may well occur but they are likely under-reported without the use of advanced genetic testing technology. For example, dozens of FMR1 gene deletions (full, partial, or mosaicism) have been reported in individuals with features of FXS, specifically using microarray analysis and recently reviewed (Ciaccio et al., 2017; Coffee et al., 2009; Gonçalves et al., 2016; Hammond, Macias, Tarleton, & Pai, 1997) . Additionally, known noncoding FMR1 polymorphisms or gene variants are summarized in Table 2 . These reports and data are beyond the scope of our summary review of coding sequence variation and the reader can refer to these articles for further information on types of genetic lesions involving FMR1. Thus, the advent of next generation DNA sequencing may allow for a much more rapid detection of non-CGG repeat FMR1 mutations and number of affected individuals identified, impacting diagnosis, genetic counseling, and testing of at-risk family members. Ultimately, their discovery and reporting may lead to a better understanding of the function of FMRP, particularly at the synapse, impacting novel treatment approaches for those with rare FMR1 gene mutations. Knowing the relationship between specific mutations and the differential effect of FMRP on pre-synaptic and/or post-synaptic function would be of interest and should be further studied in other clinical cases and animal models.
